You are here

  • Home
  • Archive
  • Volume 61, Issue 12
  • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Article info

Article menu
Download PDFPDF
Original articles
Inflammatory bowel disease
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Authors

  1. Correspondence to Dr Wolfgang Hueber, Novartis Institutes for BioMedical Research, Basel, Switzerland; wolfgang.hueber{at}novartis.com
View Full Text

Citation

Hueber W, Sands BE, Lewitzky S, et al
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Gut 2012;61:1693-1700.

Publication history

  • Revised March 14, 2012
  • Accepted March 15, 2012
  • First published May 17, 2012.
Online issue publication 
October 26, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions